Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

ImaRx Therapeutics and Philips collaborate on microbubble treatment for ischemic stroke

Philips Medical Systems : 05 November, 2007  (New Product)
ImaRx Therapeutics and Philips Electronics are to collaborate on the evaluation of Philips ultrasound technology as part of ImaRx’s SonoLysis programme to develop new treatment for acute ischemic stroke.
Under the agreement, Philips’ Medical Systems division will provide Ultrasound devices and technical assistance to ImaRx during laboratory and preclinical studies. The objective of the collaboration is to determine the optimal Ultrasound parameters to use with ImaRx’s proprietary MRX-801 microbubble technology.

Stroke is currently the third leading cause of death, and the leading cause of disability, in the USA. Approximately 3 million Americans are currently disabled from stroke, and the American Stroke Association estimates that about $62.7 billion will be spent in the U.S. in 2007 for stroke-related medical costs.

The vast majority of strokes, approximately 87 percent according to the American Stroke Association, are ischemic strokes, meaning that they are caused by blood clots that block normal blood flow in the vessels of the brain. Additionally, Datamonitor reports that less than six percent of these ischemic stroke patients receive the thrombolytic drug tPA, the only drug currently approved by the FDA to treat acute ischemic stroke.

“There is a tremendous need for new ways to treat ischemic stroke patients,” said Anne LeGrand, senior vice president and general manager, Ultrasound, for Philips Medical Systems. “Philips recognises the promise of microbubble therapies, and we are pleased to play a role in helping ImaRx advance this important potential treatment. The effort is perfectly aligned with our focus on improving patient care.”

“This research collaboration represents a significant step forward for ImaRx’s SonoLysis program,” said Bradford A Zakes, president and CEO of ImaRx Therapeutics. “By working closely with Philips Medical Systems, we are incorporating the leading Ultrasound technology and expertise into the early stages of product development, which strengthens our position as we move further through our clinical trials.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo